Response of steroid-resistant graft-versus-host disease to lymphoblast antibody CBL1

Lancet. 1995 Sep 23;346(8978):805-6. doi: 10.1016/s0140-6736(95)91621-0.


Therapy of steroid-resistant graft-versus-host disease (GVHD) with antibodies to T cells or cytokines is of limited value because GVHD is mediated by a pleomorphic group of effective cells and cytokines. CBL-1, a murine monoclonal antibody, recognises an antigen on activated T cells, B cells, and natural killer cells. We administered CBL-1 to ten patients with grade III or IV steroid-resistant GVHD. Complete remissions occurred in five cases and partial remissions in four. The organ system(s) affected by GVHD was not a predictor of response. CBL-1 was well tolerated and did not exacerbate post-transplant immunodeficiency. Our findings support the use of CBL-1 in primary prophylaxis for GVHD.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adolescent
  • Adult
  • Antibodies, Monoclonal / therapeutic use*
  • Antigens, Differentiation / immunology*
  • B-Lymphocytes / immunology
  • Child
  • Child, Preschool
  • Drug Resistance
  • Female
  • Forecasting
  • Glycolipids / immunology*
  • Graft vs Host Disease / classification
  • Graft vs Host Disease / prevention & control
  • Graft vs Host Disease / therapy*
  • Humans
  • Immunocompromised Host
  • Immunoglobulin M / therapeutic use*
  • Infant
  • Killer Cells, Natural / immunology
  • Lymphocyte Activation / immunology
  • Male
  • Membrane Lipids / immunology*
  • Methylprednisolone / therapeutic use*
  • Remission Induction
  • T-Lymphocytes / immunology
  • Transplantation Immunology


  • Antibodies, Monoclonal
  • Antigens, Differentiation
  • Glycolipids
  • Immunoglobulin M
  • Membrane Lipids
  • Methylprednisolone